Vanguard Group’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,451,205
| Closed | -$2.89M | – | 4383 |
|
|
2025
Q2 | $2.89M | Sell |
1,451,205
-134,463
| -8% | -$246K | ﹤0.01% | 3401 |
|
|
2025
Q1 | $2.3M | Sell |
1,585,668
-20,505
| -1% | -$37.9K | ﹤0.01% | 3453 |
|
|
2024
Q4 | $3.32M | Buy |
1,606,173
+32,789
| +2% | +$61.6K | ﹤0.01% | 3413 |
|
|
2024
Q3 | $2.77M | Buy |
1,573,384
+169,186
| +12% | +$434K | ﹤0.01% | 3451 |
|
|
2024
Q2 | $20.3M | Buy |
1,404,198
+41,526
| +3% | +$571K | ﹤0.01% | 2561 |
|
|
2024
Q1 | $22.7M | Sell |
1,362,672
-102,168
| -7% | -$1.63M | ﹤0.01% | 2539 |
|
|
2023
Q4 | $23.5M | Buy |
1,464,840
+310,973
| +27% | +$4.13M | ﹤0.01% | 2518 |
|
|
2023
Q3 | $15.5M | Buy |
1,153,867
+250,200
| +28% | +$3.52M | ﹤0.01% | 2658 |
|
|
2023
Q2 | $15.5M | Buy |
903,667
+412,033
| +84% | +$6.39M | ﹤0.01% | 2703 |
|
|
2023
Q1 | $8.13M | Sell |
491,634
-209,848
| -30% | -$3.36M | ﹤0.01% | 3054 |
|
|
2022
Q4 | $11.7M | Buy |
701,482
+71,728
| +11% | +$1.29M | ﹤0.01% | 2881 |
|
|
2022
Q3 | $10.8M | Buy |
629,754
+18,947
| +3% | +$275K | ﹤0.01% | 2928 |
|
|
2022
Q2 | $6.68M | Buy |
+610,807
| New | +$7.25M | ﹤0.01% | 3215 |
|
Vanguard Group's HLVX Position: Q3 2025 in Review
Vanguard Group sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 1,451,205 shares — an estimated $2.89M sold.
Vanguard Group first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $23.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Vanguard Group reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Vanguard Group sold 1,451,205 HilleVax shares in Q3 2025, an estimated $2.89M.
- Vanguard Group first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Vanguard Group's HilleVax position peaked at $23.5M in Q4 2023.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.